Ela Pharma is a biotechnology company developing innovative drugs designed to address clinical conditions caused by necrosis. The companys drug-development process is based on a new platform for anti-necrosis technology. The prevention and treatment of necrosis is significant to the treatment of numerous pathological conditions and diseases. Ela Pharmas technology is based on a novel approach that directly inhibits an intracellular proteolytic enzyme that plays a critical role in the regulation of necrosis pathways. Ela Pharmas first line of anti-necrosis agents is based on small molecules with structural features suitable for inhibiting a specific cellular target, which were found to significantly inhibit cell necrosis at particularly low concentrations.